{
    "ticker": "SGHC",
    "name": "Siga Health",
    "description": "Siga Health is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics to address significant unmet needs in infectious disease management. Founded in 2010, Siga focuses primarily on the development of antiviral therapies, leveraging advanced technologies to create innovative solutions for serious illnesses such as smallpox and other viral infections. The company's lead product, Tecovirimat, is a treatment for smallpox that has received FDA approval and is part of the strategic national stockpile to protect against bioterrorism. Siga Health is committed to research and development, working in collaboration with government agencies and international organizations to ensure the availability of effective antiviral treatments. With a robust pipeline of potential therapies, Siga aims to expand its portfolio to include treatments for emerging infectious diseases, thereby enhancing global health security. The company\u2019s mission emphasizes a proactive approach to infectious disease threats, harnessing scientific expertise to develop products that can be rapidly deployed in public health emergencies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2010",
    "website": "https://www.siga.com",
    "ceo": "Philippe L. G. C. de Lussanet",
    "social_media": {
        "twitter": "https://twitter.com/SigaHealth",
        "linkedin": "https://www.linkedin.com/company/siga-health/"
    },
    "investor_relations": "https://www.siga.com/investor-relations/",
    "key_executives": [
        {
            "name": "Philippe L. G. C. de Lussanet",
            "position": "CEO"
        },
        {
            "name": "David H. Dodd",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Antiviral Therapies",
            "products": [
                "Tecovirimat"
            ]
        }
    ],
    "seo": {
        "meta_title": "Siga Health | Innovative Antiviral Therapeutics",
        "meta_description": "Explore Siga Health, a biopharmaceutical company focused on developing antiviral therapies for infectious diseases like smallpox. Learn about our mission and products.",
        "keywords": [
            "Siga Health",
            "Antiviral Therapy",
            "Biopharmaceuticals",
            "Infectious Diseases",
            "Tecovirimat"
        ]
    },
    "faq": [
        {
            "question": "What is Siga Health known for?",
            "answer": "Siga Health is known for its development of antiviral therapies, particularly Tecovirimat for smallpox."
        },
        {
            "question": "Who is the CEO of Siga Health?",
            "answer": "Philippe L. G. C. de Lussanet is the CEO of Siga Health."
        },
        {
            "question": "Where is Siga Health headquartered?",
            "answer": "Siga Health is headquartered in New York City, New York, USA."
        },
        {
            "question": "What is Tecovirimat?",
            "answer": "Tecovirimat is an antiviral treatment approved for the treatment of smallpox."
        },
        {
            "question": "When was Siga Health founded?",
            "answer": "Siga Health was founded in 2010."
        }
    ],
    "competitors": [
        "MRNA",
        "NVAX",
        "PFE",
        "GILD"
    ],
    "related_stocks": [
        "JNJ",
        "ABBV",
        "BMY",
        "AMGN"
    ]
}